Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk ...

Denmark-headquartered Novo Nordisk (NVO) has entered into a collaboration and exclusive worldwide license agreement with ...

The upfront and near-term payment, backed by milestones that could take the total value of the licensing deal to around ... scalability," he said. Novo Nordisk and Septerna will jointly carry ...

Novo Nordisk reached an important R&D milestone on May 14, announcing a deal worth up to $2.2 billion with Septerna to develop drugs to treat obesity and other cardiometabolic diseases.

Septerna announced a global collaboration with Novo Nordisk to discover and develop oral small molecule therapies for obesity, type 2 diabetes, and cardiometabolic diseases. The deal includes more ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...